Skip to main content
SpringerLink
Log in

Disease Management Update

  • From the World Literature
  • Published:
Disease Management & Health Outcomes

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Pharmacoeconomics & Outcomes News provides comprehensive coverage of the biomedical literature on health economics and outcomes research, and summarizes information selected from more than 1600 journals. The use of tradenames, identified by [∼] or the use of a registered (®) or trademark (™) symbol, is for product identification purposes only and does not imply endorsement.

  2. * The analysis was fully funded by Novartis, with which two of the researchers were affiliated.

  3. * Behavioural graded activity comprised concepts of operant conditioning with exercise treatment in booster sessions. Usual care was provided according to the Dutch physiotherapy guideline for OA of the hip and/or knee.

  4. * The study received financial support from Boehringer Ingelheim, with which one of the authors was affiliated.

  5. ** Costs (2004 values) were those associated with inpatient, outpatient and emergency room hospital services, and pharmacy services.

  6. * Costs (2003 values) were those associated with general-practitioner and psychiatrist visits, social work, physiotherapy, hospitalisation, travel time, and lost productivity.

  7. * Costs were those associated with oral triptans and lost productivity.

  8. * Supported by Rx&D, Canada’s research-based pharmaceutical companies.

  9. ** 2003 Canadian dollars.

  10. * Direct costs only, estimated from the US and Italian health care system perspectives; costs and life-years were discounted at a rate of 3% per annum.

  11. ** Direct costs only (2005 values, estimated from a societal perspective); costs and QALYs were discounted at a rate of 3% per annum.

  12. * This study was funded by H. Lundbeck A/S.

  13. * Targets recommended by the National Heart Foundation and the Royal Australian College of General Practitioners (RACGP) Diabetes Management in General Practice guideline.

  14. * Between March and May 2002.

  15. ** Between March and May 2003.

References

  1. Firth J. Should you tell patients about beneficial treatments that they cannot have? No. BMJ 2007 Apr 21; 334(7598): 827

    Article  PubMed  Google Scholar 

  2. Marcus R. Should you tell patients about beneficial treatments that they cannot have? Yes. BMJ 2007 Apr 21; 334(7598): 826

    Article  PubMed  Google Scholar 

Reference

  • Wong JB, Pauker SG. Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B. 42nd Annual Meeting of the European Association for the Study of the Liver [online]. Available from URL: http://www.easl.ch/liver-meeting [Accessed 2007 Apr 11]

Reference

  • Horn FE, Mandryk JA, Mackson JM, et al. Measurement of changes in antihypertensive drug utilisation following primary care educational interventions. Pharmacoepidemiol Drug Saf 2007 Mar; 16(3): 297–308

    Article  PubMed  Google Scholar 

Reference

  • Ackermann R. Fitness program may reduce diabetic-care costs. Disease Management News 2007 Feb 10; 12(3): 4–5

    Google Scholar 

Reference

  • Ackermann R. Fitness program may reduce diabetic-care costs. Disease Management News 2007 Feb 10; 12(3): 4–5

    Google Scholar 

Reference

  • Fowler J, Duh MS, Lobo F, et al. The health care and work loss costs associated with atopic dermatitis. J Am Acad Dermatol 2007 Feb; 56 (2 Suppl.): 68

    Google Scholar 

Reference

  • Coupé VMH, Veenhof C, van Tulder MW, et al. The cost effectiveness of behavioural graded activity in patients with osteoarthritis of hip and/or knee. Ann Rheum Dis 2007 Feb; 66(2): 215–21

    Article  PubMed  Google Scholar 

Reference

  • Shah M, Butler M, Bramley T, et al. Comparison of health care costs and co-morbidities between men diagnosed with benign prostatic hyperplasia and cardiovascular disease (CVD) and men with CVD alone in a US commercial population. Curr Med Res Opin 2007 Feb; 23(2): 417–26

    Article  PubMed  Google Scholar 

Reference

  • Cuijpers P, Smit F, Oostenbrink J, et al. Economic costs of minor depression: a population-based study. Acta Psychiatr Scand 2007 Mar; 115(3): 229–36

    Article  PubMed  CAS  Google Scholar 

Reference

  • Ramsberg J, Henriksson M. The cost-effectiveness of oral triptan therapy in Sweden. Cephalalgia 2007 Jan; 27(1): 54–62

    Article  PubMed  CAS  Google Scholar 

Reference

  • Crémieux P-Y, Ouellette P, Petit P. Do drugs reduce utilisation of other healthcare resources? Pharmacoeconomics 2007; 25(3): 209–21

    Article  PubMed  Google Scholar 

References

  1. Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2007 Feb; 25(6): 625–33

    Article  PubMed  Google Scholar 

  2. Kurian AW, Newton Thompson R, Gaw AF, et al. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol 2007 Feb; 25(6): 634–41

    Article  PubMed  CAS  Google Scholar 

  3. Hillner BE, Smith TJ. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? J Clin Oncol 2007 Feb; 25(6): 611–3

    Article  PubMed  Google Scholar 

Reference

  • Fantino B, Moore N, Verdoux H, et al. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder. Int Clin Psychopharmacol 2007 Mar; 22(2): 107–15

    Article  PubMed  Google Scholar 

Reference

  • Thomas MC, Nestel PJ. Management of dyslipidaemia in patients with type 2 diabetes in Australian primary care. Med J Aust 2007 Feb 5; 186(3): 128–30

    PubMed  Google Scholar 

Reference

  • Gladding P, Larsen F, Durrant H, et al. Education together with a preprinted sticker improves the prescribing of prophylactic enoxaparin. NZ Med J 2007 Mar 23; 120(1251): 57–66

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Disease Management Update. Dis-Manage-Health-Outcomes 15, 193–198 (2007). https://doi.org/10.2165/00115677-200715030-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-200715030-00007

Keywords

Search

Navigation